Table 5 The top 30 most frequent adverse events for rotigotine excluding common medication co-usage at the PT level from FAERS data

Product Adhesion Issue*

1264

160.34 (151.19–170.04)

147.15 (175675.65)

140.85 (134.1)

7.14 (5.47)

Drug Ineffective*

548

1.64 (1.5–1.78)

1.61 (130.25)

1.61 (1.5)

0.69 (-0.98)

Death*

473

2.17 (1.98–2.38)

2.14 (290.25)

2.14 (1.98)

1.1 (-0.57)

Application Site Erythema*

366

55.94 (50.39–62.11)

54.63 (18959.93)

53.75 (49.24)

5.75 (4.08)

Application Site Pruritus*

363

65.95 (59.37–73.26)

64.41 (22229.51)

63.18 (57.86)

5.98 (4.32)

Device Adhesion Issue*

362

103.72 (93.3–115.29)

101.28 (34871.71)

98.27 (89.94)

6.62 (4.95)

Off Label Use*

323

1.55 (1.39–1.73)

1.54 (62.36)

1.54 (1.41)

0.62 (-1.04)

Overdose*

306

5.39 (4.82–6.04)

5.31 (1071.41)

5.3 (4.82)

2.41 (0.74)

Parkinson’S Disease*

213

45.97 (40.12–52.67)

45.34 (9112.88)

44.73 (39.92)

5.48 (3.82)

Fall*

212

2.52 (2.2–2.89)

2.5 (191.58)

2.5 (2.23)

1.32 (-0.35)

Application Site Reaction*

191

132.75 (114.77–153.54)

131.1 (23711.11)

126.08 (111.63)

6.98 (5.31)

Tremor*

190

4.58 (3.97–5.28)

4.53 (523.69)

4.53 (4.02)

2.18 (0.51)

Restless Legs Syndrome*

189

40.9 (35.41–47.25)

40.41 (7177.46)

39.93 (35.39)

5.32 (3.65)

Application Site Rash*

180

48.55 (41.87–56.29)

47.99 (8163.67)

47.31 (41.8)

5.56 (3.9)

Insomnia*

175

2.6 (2.24–3.02)

2.58 (170.57)

2.58 (2.28)

1.37 (-0.3)

Nausea

171

0.86 (0.74–1.01)

0.87 (3.59)

0.87 (0.76)

-0.21 (-1.87)

Dizziness*

151

1.21 (1.03–1.42)

1.21 (5.44)

1.21 (1.06)

0.27 (-1.39)

Somnolence*

137

2.74 (2.32–3.25)

2.73 (150.25)

2.73 (2.37)

1.45 (-0.22)

Wrong Technique In Product Usage Process*

130

2.51 (2.12–2.99)

2.5 (117.48)

2.5 (2.16)

1.32 (-0.34)

Hallucination*

128

7.05 (5.92–8.39)

7 (657.71)

6.99 (6.04)

2.8 (1.14)

Pruritus*

116

1.3 (1.08–1.56)

1.3 (7.97)

1.3 (1.11)

0.38 (-1.29)

Rash*

114

1.07 (0.89–1.28)

1.07 (0.46)

1.07 (0.91)

0.09 (-1.58)

Pneumonia*

110

1.36 (1.13–1.64)

1.36 (10.43)

1.36 (1.16)

0.44 (-1.22)

Intentional Product Misuse*

109

4.74 (3.93–5.73)

4.71 (319.05)

4.71 (4.02)

2.24 (0.57)

Product Dose Omission Issue*

106

1.87 (1.54–2.26)

1.86 (42.52)

1.86 (1.59)

0.9 (-0.77)

Therapy Interrupted*

103

7.53 (6.2–9.14)

7.49 (578.03)

7.47 (6.35)

2.9 (1.24)

Product QualityIssue*

102

2.68 (2.21–3.26)

2.67 (106.8)

2.67 (2.27)

1.42 (-0.25)

Fatigue

97

0.48 (0.4–0.59)

0.49 (53.02)

0.49 (0.41)

-1.04 (-2.7)

Application Site Irritation*

87

28.44 (23.02–35.14)

28.28 (2270.62)

28.05 (23.5)

4.81 (3.14)

Gait Disturbance*

87

1.7 (1.38–2.1)

1.7 (25.2)

1.7 (1.43)

0.77 (-0.9)